TSThomas Sycha

Thomas Sycha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Sycha has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Eduard Auff

    Department of Neurology, Medical University of Vienna, Vienna, Austria

    4 shared publications
  • Eduard Auff

    Department of Neurology, Medical University of Vienna, Vienna, Austria

    3 shared publications
  • Gottfried Kranz

    Department of Neurology, Medical University of Vienna, Vienna, Austria

    3 shared publications
  • Hans-Georg Eichler

    Medical University of Vienna; Department of Clinical Pharmacology; Allgemeines Krankenhaus Währinger Gürtel 18-20 Vienna Austria A-1090

    3 shared publications
  • Peter Schnider

    Department of Neurology, Landeskrankenhaus, Grimmenstein‐Hochegg, Austria

    3 shared publications
  • Anna Paul

    Department of Neurology Medical University of Vienna Vienna Austria

    2 shared publications

Latest Publications

  • Open Access

    The effect on blink frequency of a selective blue-filtering photochromic lens in patients with benign essential blepharospasm

    by Tobias Monschein, Tobias Zrzavy, Corinna Weber, Zoya Kuzmina, Walter Gutstein, Thomas Sycha

    Objective: The aim of this clinical study was to assess the impact of a non-invasive selective blue-filtering photochromic lens coating Crizal Prevencia on the treatment and response of benign essential blepharospasm (BEB).Patients and methods: Twenty-four patients were recruited in the outpatient clinic of the Medical University of Vienna in a randomized, double-blind, cross-over study design. Blink frequencies were assessed in patients with BEB before and 14 days after intervention with either a filtering ophthalmic lens or a placebo lens, respectively. Outcome parameters include sub-group analysis of a blink frequency under six different conditions: three photopic conditions, one resting condition, one reading condition, and one video game condition.Results: From 24 recruited patients, 15 patients were available for final analysis. Comparing the optical blue filtering lens to placebo, showed a reduced blink frequency in specific subtests, but not compared to baseline.Discussion: In conclusion, optical filtering glasses might have a beneficial effect on BEB and provide a non-invasive therapeutic add-on option, in addition to botulinum neurotoxin therapy, for patients with BEB and should necessarily be further investigated in a multicenter setting, resulting in larger sample sizes to gain valid information about the effect of photochromic blue filter glasses in BEB.Clinical trial registration: https://drks.de/search/en/trial/DRKS00032135, DRKS00032135.

  • Open Access

    Estimation of patent foramen ovale size using transcranial Doppler ultrasound in patients with ischemic stroke

    by Anna Grisold, Walter Rinner, Anna Paul, Harald Gabriel, Uros Klickovic, Michael Wolzt, Martin Krenn, Fritz Zimprich, Gabriel Bsteh, Thomas Sycha

    Background and Purpose: Patent foramen ovale (PFO)is associated with cryptogenic stroke, especially in young adults. Transcranial Doppler (TCD) ultrasound is used as a screening tool before transesophageal echocardiography (TEE). However, the use of Valsalva maneuver (VM) to identify a right‐to‐left‐shunt underlies interindividual variability. Here, we aimed to assess whether a pressure‐controlled standardization of VM is useful to estimate PFO size.Methods: We included patients aged 18–80 years with a PFO according to TEE. Subjects underwent TCD with microembolic signals (MES) counted under four pressure conditions (i.e., at rest, 15 mbar, 40 mbar, and maximum expiratory pressure). Findings were correlated with TEE‐based PFO size. The predictive value of TCD at rest and VM‐based TCD for PFO size estimation was assessed by stepwise multivariate linear regression models and multiple cross‐tab‐analyses.Results: We screened 203 subjects after a cerebrovascular event, of which 78 (48 males [61.5%], median age 55 years [22–80]) with PFO were included. We found an association between MES count and expiratory pressure (p < .001). Predefined MES count categories at TCD pressure conditions correlated significantly with PFO size measured by TEE. We propose a PFO size estimation model based on TCD at rest and under VM, which classified PFO size correctly in 64.1% with the highest accuracy for small PFOs.Conclusion: Our data provide evidence that TCD with step‐wise barometric standardization allows an estimation of PFO size with good accuracy. Though TCD will not replace TEE in future, this might be of clinical value in circumstances where TEE cannot be easily performed.


  • Plasticity of static graviceptive function in patients with cervical dystonia

    by Kirsten Platho-Elwischger, Gottfried Kranz, Thomas Sycha, Daniela Dunkler, Paulus Rommer, Christian Mueller, Eduard Auff, Gerald Wiest


  • Intramuscular distribution of botulinum toxin—Visualized by MRI

    by K. Elwischger, G. Kasprian, M. Weber, M. Meyerspeer, C. Linder, E. Auff, D. Prayer, T. Sycha, G. Kranz


  • Open Access

    Early treatment with IgM-enriched intravenous immunoglobulin does not mitigate critical illness polyneuropathy and/or myopathy in patients with multiple organ failure and SIRS/sepsis: a prospective, randomized, placebo-controlled, double-blinded trial

    by Richard Brunner, Walter Rinner, Christine Haberler, Reinhard Kitzberger, Thomas Sycha, Harald Herkner, Joanna Warszawska, Christian Madl, Ulrike Holzinger

    Introduction: Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical illness. Retrospective data suggest that early application of IgM-enriched intravenous immunoglobulin (IVIG) may prevent or mitigate CIPNM. Therefore, the primary objective was to assess the effect of early IgM-enriched IVIG versus placebo to mitigate CIPNM in a prospective setting. Methods: In this prospective, randomized, double-blinded and placebo-controlled trial, 38 critically ill patients with multiple organ failure (MOF), systemic inflammatory response syndrome (SIRS)/sepsis, and early clinical signs of CIPNM were included. Patients were randomly assigned to be treated either with IgM-enriched IVIG or placebo over a period of three days. CIPNM was measured by the CIPNM severity sum score based on electrophysiological stimulation of the median, ulnar, and tibial nerves on days 0, 4, 7, 14 and on the histological evaluation of muscle biopsies on days 0 and 14 and ranged from 0 (no CIPNM) to 8 (very severe CIPNM). Results: A total of 38 critically ill patients were included and randomized to receive either IgM-enriched IVIG (n = 19) or placebo (n = 19). Baseline characteristics were similar between the two groups. CIPNM could not be improved by IVIG treatment, represented by similar CIPNM severity sum scores on day 14 (IVIG vs. placebo: 4.8 ± 2.0 vs. 4.5 ± 1.8; P = 0.70). CIPNM severity sum score significantly increased from baseline to day 14 (3.5 ± 1.6 vs. 4.6 ± 1.9; P = 0.002). After an interim analysis the study was terminated early due to futility in reaching the primary endpoint. Conclusions: Early treatment with IVIG did not mitigate CIPNM in critically ill patients with MOF and SIRS/sepsis. Trial registration: Clinicaltrials.gov: NCT01867645


  • Long-term efficacy and respective potencies of botulinum toxin A and B: a randomized, double-blind study

    by G. Kranz, A. Paul, B. Voller, M. Posch, C. Windischberger, E. Auff, T. Sycha

    Mouse units (mU) are used for quantification of the biological activity of botulinum A and B toxin preparations. However, in human tissue, mU values between preparations are not equivalent and lack of clarity concerning efficacy and safety remains with regard to their respective potencies, duration of drug effect and diffusion qualities. To compare short-term and long-term effects of Botox(®) (BOT; Allergan Inc., Irvine, CA, U.S.A.) and Neurobloc(®)/Myobloc(®) (NBC; Solstice Neurosciences Inc., Malvern, PA, U.S.A.) in different doses and dilutions in a human skin model. In this prospective randomized double-blind study, 18 healthy volunteers (eight women and 10 men; mean ± SD age 28·4 ± 5·7 years) were injected intradermally with pure saline, BOT and NBC at 10 points in the abdomen in random order, using the BOT/NBC conversion ratio 1 : 75 and different dilution schemes. For an objective outcome, the ninhydrin sweat test was used to compare the anhidrotic areas (action halos). Ten measurements were taken during a time period of 54 weeks. Both preparations showed a peak effect at week 3, with significantly larger anhidrotic areas for NBC. Thereafter, however, the rate of decline was lower in BOT and after week 24, mean BOT areas were larger. The effect of dilution was higher in NBC and the mean dose equivalence conversion ratio (BOT/NBC) was 1 : 29 (area under the curve). Gender effects were seen in both products, with smaller action halos in women. These results have important implications in clinical routine, especially for autonomic indications.


  • Diode laser hair removal does not interfere with botulinum toxin A treatment against axillary hyperhidrosis

    by Anna Paul, Gottfried Kranz, Andreas Schindl, Georg S. Kranz, Eduard Auff, Thomas Sycha

    Background and Objective: The possible interference of combined laser hair removal and Botulinum toxin A (BoNT/A) injections in the treatment of axillary hyperhidrosis has not previously been explored. In order to examine this potential interference, we assessed the effect of BoNT/A on axillary hyperhidrosis with and without concomitant diode laser axillary hair removal.Study Design/Materials and Methods: In a prospective, double blind, randomized cross over trial, nine patients suffering from primary axillary hyperhidrosis were laser‐treated on one randomly assigned axilla. One week later, both axillas were injected intradermally with BoNT/A (100 MU per axilla). During the same session, the previously untreated axilla was lasered. Axillary sweat rates (in g/5 minutes.) were determined by gravimetry and compared at rest, during mental exercise, and during physical exercise. Additionally, subjective outcome measures were assessed by a visual analogue scale, Dermatology Life Quality Index, and Global Clinical Impression score.Results: No differences were found regarding the effect of BoNT/A on previously laser‐treated and laser co‐treated sides over time course for any of the outcome parameters. Sweat production was reduced 3 weeks after BoNT/A treatment by 93.5% at rest, 96.5% during mental exercise, and 67% during physical exercise.Conclusions: Concomitant laser hair removal does not interfere with BoNT/A treatment on axillary hyperhidrosis. Lasers Surg. Med. 42:211–214, 2010.